Purpose: e purpose of this study was to investigate the e ects of advanced glycation end-products (AGEs) on the components of the renin-angiotensin system (RAS) in podocytes and to understand the mechanism of these e ects.
Diabetic nephropathy (DN) is a serious complication of diabetes and, ultimately, it progresses to glomerular sclerosis and end-stage renal disease (ESRD). Current evidence indicates that AGEs increase at an accelerated rate in diabetes and are associated with the development of severe diabetic complications1. Since the glomerular capillary wall functions as an ecient and selective barrier, podocytes are critically involved in maintaining the glomerular ltration barrier; damage to podocytes can lead to proteinuria and initiate glomerulosclerosis, which can result in the progressive loss of kidney function [2] .
Accumulating evidence supports the idea that the intrarenal RAS plays an important role in progressive kidney disease; suppression of the RAS with either ACE inhibitors or AT1R antagonists reduces proteinuria and retards the progression of DN [3, 4] . Singh et al. found an increased Ang II and renin content in glomerular extracts obtained from streptozotocininduced diabetic rats [5] . Local RAS is activated in mesangial cells [6] and proximal tubular cells [7] by high glucose and in podocytes by mechanical stress [8] . However, the e ects of AGEs on the RAS in podocytes are still uncertain and a clear understanding of the mechanism of how AGEs activate the RAS in podocytes is lacking.
Phosphoinositide 3-kinase (PI3-K) and its downstream mediator, Akt, play a central role in a diverse range of cellular responses including cell growth, survival, proteolysis and malignant transformation [9.10] . While recent studies have shown that the activation of PI3-K may play a part in diabetic complications [11] [12] [13] , its role in diabetic nephropathy, especially in the context of activated RAS, is relatively unstudied. e purpose of this investigation was to characterize the e ects of AGEs on the components of the RAS. How AGEs activated the RAS was examined with anti-RAGE antibody and PI3-K inhibitor to identify the underlying pathway involved.
Methods

Podocytes culture
A conditionally-immortalized mouse podocyte cell line was generously provided by Dr. Peter Mundel (Harvard Medical School, Boston, MA, USA). Cells were harvested as previously described [14] . Cells were cultured in a non-permissive condition in 10% fetal bull serum with 10 U/ml INF-γ in RPMI 1640 media at 33°C. When podocytes were 60-80% con uent, they were transferred to 37°C and incubated for 7-10 days to allow di erentiation. Passages 8-14 were used for all experiments. Before treatment, di erentiated podocytes were cultured in media containing 1% fetal bull serum for 24 hours. LY294002 was purchased from Sigma-Aldrich.
MTT assay for cell proliferation
Podocyte viability was assessed using the MTT (3- [4, 5] dimethylthiazol-2,5-diphenyltetrazolium bromide) assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. is assay is a nonradioactive cell proliferation assay that identi es living cells and is based on the cellular conversion of a tetrazolium salt into a formazan product; a chromophore that can be quanti ed by spectrophotometry. Brie y, podocytes were plated in a 96-well plate and were allowed to adhere overnight; then, an appropriate concentration of AGEs was added and incubated with the podocytes for 24 hours. A labeling dye included in the kit was added 4 hours prior to the end point. e stop solution was then added to each well to stop the reaction and solubilize the cells and the absorbance was read at 490 nm using a SPECTRAmax (Molecular Devices, Sunnyvale, CA, USA).
Lactate dehydrogenase (LDH) assay
Con uent podocytes were cultured under control and experimental conditions. Supernatants were collected, centrifuged for 10 min at 2000 x g and were assessed for LDH release using a LDH cytotoxicity kit according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing City, China). e cytotoxicity of the control and experimental samples was expressed as the percentage of LDH release compared with the total intracellular LDH content. e latter was determined by lysis of representative cell monolayers using 2% Triton X-100 (v/v).
Angiotensin-con erting enzyme (ACE) activity
ACE activity in the media and cell lysates was determined as previously described [15] using a commercial kit (Navy General Hospital, Beijing, China). Hippuryl-histidyl-leucine is hydrolyzed to hippuric acid and histidyl-leucine in the presence of exogenous ACE. Hippuric acid was extracted with ethyl acetate. e extracted liquor was evaporated to dryness at 130°C for 15 min and was then dissolved in 1 M NaCl. e mixture was monitored by UV spectrophotometry at 228 nm. One unit of ACE activity was de ned as the amount of enzyme required to release 1 nmol of hippuric acid per minute per milliliter of sample.
Measurement of Ang II
Ang II levels were determined in cell lysates and media. Podocytes were harvested in 1% FBS medium for 24 hours and then cultured in control and experimental conditions. e cells were washed with ice-cold PBS, scraped in extraction bu er and homogenized. Cell lysates and media were centrifuged at 12,000 x g for 10 minutes at 4°C and supernatants were collected. Ang II levels in the cell lysates and the media were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (RayBiotech, Norcross, GA, USA) according to the manufacturer's instructions.
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from podocytes using Trizol reagent (Invitrogen, Carlsbad CA, USA) according to the manufacturer's instructions. Total RNA (500 ng) from each group was reverse transcribed using the reverse transcriptase (RT) provided in a SYBRPremix Ex Taq kit (Perfect Real Time,TaKaRa, Otsu, Shiga, Japan). Reactions were carried out at 37 °C for 15 min and then 85 °C for 5 s. e primers used in the experiments are listed in Table 1 . PCR was performed by using an ABI Prism 7000 sequence detection system (AppliedBiosystems, Foster City, CA, USA) and a SYBRPremix Ex Taq Perfect Real Time kit,
Western blot
Podocytes were washed twice with cold PBS and scraped with lysis bu er containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 nM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin (Cell Signaling Technology, Beverly, MA, USA) and protease and phosphatase inhibitor cocktail tablets (Roche Diagnostics, Mannheim, Germany). Protein concentrations were determined with the Bradford reaction. A total of 50 μg of boiled extracts was loaded on 8% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to polyvinylidene uoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). e membranes were blocked in 5% fat-free milk before incubation with antibody. e following primary antibodies were used: rabbit anti-AGT (1:2000, Epitomics, Birlingame, CA, USA), rabbit anti-AT1R, rabbit anti-AT2R and rabbit anti-renin (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA). A total of 20 μg of boiled extracts was loaded on 8% SDS-PAGE gels and incubated with rabbit anti-RAGE (1:2000, SigmaAldrich, St. Louis, MO, USA ), rabbit anti-phospho-Akt and mouse anti-Akt (1:2000, Cell Signal Technology, Danvers, MA, USA). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology Inc); bands were detected using the ECL chemiluminescence system (Millipore, Billerica, MA, USA).
Measuring of apoptosis
Apoptosis of podocytes was measured at 24 hours by ow cytometry (Annexin-FITC apoptosis diction Kit, BD Biosciences Pharmingen, city, country). Cells were washed twice with cold PBS, were scraped into 1×binding bu er to make a cell suspension at a concentration of 1×10 6 cells/ml and then 100 μL of the cell suspension were transferred to a 5 ml tube. With 5 μL of Annexin V-FITC and 5 μL of propidium iodide, the cells were gently mixed and incubated for 15 min at room tem- AGT: angiotensinogen n; AT1R: angiotensin II type 1 receptor; AT AT2R: angiotensin II type 2 receptor perature in the dark and then 400μL 1×binding bu er were added to each tube. Samples were analyzed by ow cytometry (BD FACSCalibur, San Jose, CA, USA) within 1 h, with excitation at 488 nm and emission collected at 525 nm (FITCconjugated AV-labeled cells) and 620 nm (PIlabeled cells). Single labeling was used to gate and control for bleed-through. e cell population was characterized according to whether it was labeled with neither AV nor PI (viable), PI alone (necrotic), AV alone (early apoptotic), or both PI and AV (late apoptotic). e apoptosis rate of podocytes were summarized as early apoptotic plus late apoptotic.
Statistical analysis
e results are presented as the mean ± standard deviation. e statistical signi cance was assessed by a nonparametric Kruskal-Wallis ANOVA analysis or a Student's t-test. P values <0.05 were considered signi cant.
Results
AGEs did not a ect podocyte proliferation and metabolic activity
Cell proliferation and viability was assessed by the MTT assay and LDH release. To determine the optimal concentration of AGEs to be applied to podocytes, the di erentiated podocytes were incubated with concentrations of AGEs ranging from 0 to 160 μg/ml for 24 hours. Cell proliferation and viability were una ected at concentrations of AGEs of 20-80 μg/ml but higher concentrations (160 μg/ml) inhibited cell proliferation ( Figure 1A ). Measurements of LDH release con rmed that 80 μg/ml of AGEs was not cytotoxic to podocytes ( Figure 1B) ; therefore, this dose was used in all subsequent experiments.
AGEs increased the expression of AGT and AT1R in podocytes, but did not alter the expression of renin or AT2R
Incubation of podocytes in media containing 80 μg/ml AGEs produced a signi cant increase in both AGT and AT1R mRNA and protein levels compared with controls (P<0.05); however, there were no changes in the levels of renin or AT2R (P>0.05). In contrast, incubation in 80 μg/ml BSA did not increase either AGT or AT1R expression (Figure 2A, 2B ). e increase in AGT and AT1R expressions was observed within 24 hours and was maintained for up to 48 hours (P<0.05) ( Figure 2C ).
AGEs increased ACE activity
ACE in podocytes is present as a membrane-bound ectoenzyme and in a secreted form; therefore, both cell lysates and conditioned media were analyzed for ACE activity. A er a 24 hour incubation period in various concentration of AGEs, the activity of ACE in cell lysates and media increased in a dosedependent manner ( Figure 3A) . ACE activity increased at 6 hours and the increase was sustained for up to 48 hours ( Figure   Cheng 3B). No signi cant increase in ACE activity was observed in either the control or the BSA-treated group.
AGEs increased Ang II levels in podocytes
Following a 24-hour incubation in AGEs, Ang II levels were signi cantly higher in both cell lysates and conditioned media compared with controls or BSA-treated groups ( Figure 4A ). Ang II levels increased starting at 6 hours and were sustained for at least 48 hours ( Figure 4B ). ese results demonstrate that Ang II expression increased in podocytes in the presence of AGEs. In contrast, there was no signi cant di erence in Ang II concentration between the control and BSA-treated groups.
AGEs increased RAGE expression and Akt activation in podocytes
RAGE expression and the activity of Akt in cultured podocytes were assayed by western blot. Incubation of podocytes in media containing 80 μg/ml AGEs for 24 hours resulted in a signi cant increase in RAGE levels compared with control and BSA-treated group (P=0.012) ( Figure 5A ). AGEs also in- creased the levels of the active form of Akt signi cantly (P=0.001) (Fig 5B) .
Pre-treatment with anti-RAGE antibody alleviated the activated RAS
Podocytes were treated for 24 hours with BSA, AGEs (80 μg/ ml) alone or AGEs plus pre-treatment with anti-RAGE antibody (50 μg/ml) for 60 minutes. Pretreatment with anti-RAGE antibody signi cantly inhibited the increase of AGT and AT1R protein expression by 37% and 34%, respectively ( Figure 6A ). ACE activity in cell lysates and media were reduced by 39% and 45%, respectively ( Figure 6B ). Ang II concentrations in cell lysates and media decreased by 52% and 53%, respectively, compared with AGEs group ( Figure 6C ).
PI3K inhibitor attenuated the activated RAS
Podocytes were treated with BSA, AGEs (80 μg/ml) alone or AGEs in combination with the PI3K inhibitor LY294002 (10 μM), captopril (100 μM) or chymastatin (50 μM). e AGEsinduced increases in the expression of AGT and AT1R were decreased by 64% and 56%, respectively ( Figure 7A ). ACE activity in cell lysates and media were reduced by 50% and 39%, respectively ( Figure 7B ). Ang II concentrations in cell lysates and media were lowered by 44% and 44% in LY294002 treated group, respectively ( Figure 7C ). Captopril alleviated the levels of Ang II by 50% and 43% in cell lysates and conditioned media, respectively; however, chymastatin did not change the levels of Ang II concentrations in cell lysates or in conditioned media. ese results indicate that the RAGE-PI3-K/Akt pathway might be involved in the activated RAS in podocytes, and ACE is the main enzyme for the production of Ang II converted from Ang I.
AGEs induced podocyte apoptosis in an Ang II-dependent fusion
To investigate biologic signi cance of AGEs-induced activation of local RAS, podocyte apoptosis was measured. As shown in Figure 8 , AGEs resulted in a near three-fold increase in apoptosis when compared with the control (23.4±4.6% vs. 7.8±3.8%, P=0.001). To con rm the apoptosis induced by AGEs was due to activation of RAS, Ang II receptor antagonist losartan (10-5 
Discussion
AGEs concentrations increased signi cantly in diabetes mellitus. e kidney is not only a target of AGEs but also a source, because declining renal function triggers a rapid increase in plasma concentrations of AGEs [16] . e intrarenal RAS plays an important role not only in the regulation of glomerular hemodynamics, but also in glomerular hypertrophy and sclerosis [17] . Several pieces of evidence have shown that high glucose and mechanical strain activate a local RAS in podocytes [8.18] . Whether AGEs activate the local RAS in podocytes, and the mechanisms underlying these events, is still unclear.
e present study has demonstrated that AGEs stimulated AGT and AT1R production in mouse podocytes. No signicant changes in the expression of renin and AT2R were observed. Although some authors found an increase in renin content in diabetic patients [5] , other authors showed low-renin state in diabetic nephropathy [19] . e levels of Ang !were higher in glomerular podocytes, which means a local RAS was activated through di erent pathway. e stimulatory e ects of AGEs on AGT and AT1R in podocytes indicate that AGEs can increase both the substrate and the receptor for the genera- ated podocytes predominantly express AT1R (about 75%) with a lesser amount of AT2R (about 25%) [20, 21] . Our data suggest that the activation of AT2R is not signi cantly involved in the functional responses to Ang II but that AT1R plays a more important role in mediating most of the physiological actions of Ang II. In fact, we speculate that the e ects of Ang II on podocytes under physiological and pathophysiological conditions are predominantly mediated by the activation of the AT1R. e formation of Ang II is mediated by ACE and non-ACE enzymes, and ACE has been established as the most important enzyme for the generation of Ang II [23] . Previous studies have reported ACE protein and activity in both glomerular and cultured podocytes. Our results demonstrated that AGEs increase ACE activity signi cantly in cell lysates and conditioned media, as compared with controls. ACE activity increased from 6 hours and persisted at 48 hours and these results are consistent with previous reports in mesangial cells [23] . Pretreatment with the ACE inhibitor, captopril, rather than the chymase inhibitor, chymastatin, ameliorated the increase of Ang II levels in AGEs-stimulated podocytes and their conditioned media. ese results imply the involvement of ACE rather than chymase pathways in AGEs-induced Ang II production in podocytes. e results are consistent with previously published results showing that chymase expression was not detected in podocytes [24] and that the chymase in- hibitor chymastatin did not change Ang II secretion induced by mechanical stress [18, 25] . Ang II, the nal e ector of the RAS, plays a key role in the pathogenesis of diabetic nephropathy, especially in podocyte injury. Podocytes possess the metabolic machinery necessary for autologous synthesis of Ang II. Mouse podocytes were subjected to various concentrations of AGEs for di erent time intervals and the levels of Ang II in the media and cell lysates were determined using a competitive ELISA. As shown in Figure 4A and B, there was a signi cant increase in Ang II levels at 24 hours and these changes were still present at 48 hours. e e ects of local RAS activation on podocyte apoptosis were also observed by ow cytometry. AGEs resulted in a near three-fold increase in apoptosis as compared with controls. Both losartan and captopril signi cantly alleviated the apoptotic podocytes induced by AGEs; however, chymastatin did not signi cantly alter the rate of apoptosis induced by AGEs . ese results imply that AGEs induced podocyte injury via activation local RAS in podocytes.
Our results show that AGEs increased the expression of RAGE in a dose-dependent manner. ese results are consistent with published reports from endothelial cells [26] , pericytes [27] , mesangial cells [23] and podocytes [12] . RAGE is a multi-ligand, immunoglobulin superfamily, cell surface receptor that is expressed in podocytes and the glomerular endothelium in the kidney. Previous studies have shown that RAGEoverexpressing diabetic mice exhibit progressive glomerulosclerosis with renal dysfunction when compared with diabetic litter mates lacking the RAGE transgene [28] . When preincubated with an anti-RAGE antibody, the AGEs-induced increases in the expression of AGT, AT1R , the levels of Ang II, and ACE activity decreased signi cantly; therefore, the AGE-RAGE interaction in podocytes could be involved in the activated RAS. Rüster found that Ang II upregulated RAGE expression via AT2R in podocytes [29] , and the upregulation of RAGE may further activate RAS .Our results show the increased levels of Ang II induce podocyte apoptosis mainly via the upregulated AT1R. ese results show the increased Ang II may cause podocyte injury via both AT1R and AT2R, which aggravates the process of DN.
Our results show that AGEs induced the activation of the Akt kinase activity signi cantly. To determine whether the ef- fects of AGEs on the RAS were PI3-kinase-dependent, the PI3-K inhibitor, LY294002, was added. LY294002 signicantly reduced the e ects of AGEs on the expression levels of AGT, AT1R and Ang II as well as attenuating the AGEsinduced increase in ACE activity. ese results indicate that the PI3-K/Akt pathway is involved in the activated RAS induced by AGEs.
Conclusion
In summary, podocytes not only respond to Ang II by activation of AT1 receptors, but also are capable of directly producing Ang II. Stimulation of Ang II production by AGEs provides a direct link between AGEs and the RAS, which may be important in the pathogenesis of DN. e following data from this study suggest that AGEs activated the RAS via the RAGE-PI3-K pathway in podocytes. First, AGEs led to the upregulation of AGT and AT1R, the increase of Ang II production and the activity of ACE. Second, AGEs increased the expression of RAGE and the active form of Akt kinase. ird, pre-treatment with an anti-RAGE antibody or the PI3-K inhibitor LY294002 signi cantly inhibited the changes induced by AGEs. us, therapies that block the ability of AGEs binding to RAGE or inhibit the PI3-K pathway may alleviate the activated RAS and delay the progression of DN. ese hypotheses deserve further investigation in vivo.
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